<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259281</url>
  </required_header>
  <id_info>
    <org_study_id>GTX-102-001</org_study_id>
    <nct_id>NCT04259281</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome</brief_title>
  <acronym>KIK-AS</acronym>
  <official_title>A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneTX Biotherapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneTX Biotherapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, multiple-dose, study to evaluate the safety, tolerability,&#xD;
      and plasma and cerebrospinal fluid (CSF) concentrations of GTX-102 in pediatric patients with&#xD;
      Angelman syndrome. Up to 20 patients (male and female) ≥ 4 and ≤ 17 years of age with a&#xD;
      genetically confirmed diagnosis of full maternal UBE3A gene deletion (within 15q11.2-q13&#xD;
      region) will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, open-label, multiple-dose, study to evaluate the safety, tolerability,&#xD;
      and plasma and CSF concentrations of GTX-102 in pediatric patients with AS.&#xD;
&#xD;
      The study includes a monthly dosing period followed by a maintenance period. Eligible&#xD;
      patients who meet all of the inclusion criteria and none of the exclusion criteria and who&#xD;
      successfully complete all screening and baseline assessments will be assigned to one of 2&#xD;
      dose cohorts based on patient age in Canada and UK; in the US all patients will enter a&#xD;
      single dose cohort. GTX-102 will be administered by intrathecal (IT) injection via lumbar&#xD;
      puncture (LP) at Baseline followed by 2-3 subsequent IT injections on study Days 30, 58 and&#xD;
      86. The procedure for IT administration of GTX-102 will performed by a clinician with&#xD;
      experience in LP and anesthetic care will be directed by experienced anesthesiologists with a&#xD;
      focus on patient safety and comfort. The duration of study for each patient in the dose&#xD;
      escalation phase is anticipated to be approximately 5 months. Patients will then transition&#xD;
      to a maintenance phase of study where they may receive continued treatment with GTX-102.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">January 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: incidence of adverse events</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Number of patients with adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: incidence of serious adverse events</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Number of patients with serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: severity of adverse events</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Severity of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of GTX-102</measure>
    <time_frame>Day 2, Day 3, Day 4, Day 30, Day 58, Day 86, Day 128 (end of study)</time_frame>
    <description>Maximum drug concentration (Cmax)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics of GTX-102</measure>
    <time_frame>Day 86</time_frame>
    <description>UBE3A protein levels in CSF</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in motor function by wearable device</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Ambulation measured by wearable device</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in development</measure>
    <time_frame>Change from baseline to Day 128 (end of study) on total score</time_frame>
    <description>Developmental assessment by Bayley Scales of Infant/Toddler Development 4 (BSID-4)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in communication</measure>
    <time_frame>Change from baseline to Day 128 (end of study) on total score</time_frame>
    <description>Observer Reported Communication Assessment (ORCA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Seizure frequency</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Seizure frequency by diary</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Change in sleep</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Assessment of sleep by diary</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Adaptive behaviors</measure>
    <time_frame>Change from baseline to Day 128 (end of study) on total score</time_frame>
    <description>Vineland Adaptive Behaviors Scale-3 (VABS-3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Global Clinical Status</measure>
    <time_frame>Day 128 (end of study)</time_frame>
    <description>Clinical Global Impression of Severity - Angelman syndrome version (CGI-S-AS)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Angelman Syndrome</condition>
  <arm_group>
    <arm_group_label>GTX-102 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.3 mg for 3-4 monthly doses followed by a quarterly maintenance regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GTX-102 Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg for 3-4 monthly doses followed by a quarterly maintenance regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GTX-102 Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg for 4 monthly doses followed by a quarterly maintenance regimen of 2 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GTX-102</intervention_name>
    <description>antisense oligonucleotide</description>
    <arm_group_label>GTX-102 Cohort 4</arm_group_label>
    <arm_group_label>GTX-102 Cohort 5</arm_group_label>
    <arm_group_label>GTX-102 Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent from parent(s) or legal guardian(s)&#xD;
&#xD;
          -  Documented genetic confirmation of full maternal UBE3A gene deletion causing AS (e.g.&#xD;
             DNA methylation testing with either a chromosomal microarray or FISH) in the region of&#xD;
             15q11.2-q13 including class I, II or III).&#xD;
&#xD;
          -  Age ≥ 4 to ≤ 17 years at screening (in US Age ≥ 4 to &lt; 8 years at screening)&#xD;
&#xD;
          -  Stable seizure control (defined as clinically stable with no changes in antiepileptic&#xD;
             medications over the prior 1 month before screening visit, other than weight&#xD;
             associated dose adjustments)&#xD;
&#xD;
          -  Platelet count, prothrombin time (PT) / international normalized ratio (INR) and&#xD;
             partial thromboplastin time (PTT) within normal limits&#xD;
&#xD;
          -  Normal renal function with serum creatinine and spot urine protein within normal&#xD;
             limits&#xD;
&#xD;
          -  Normal hepatic function with total bilirubin, aspartate aminotransferase (AST),alanine&#xD;
             aminotransferase (ALT) and alkaline phosphatase within normal limits&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, drug administration plan, laboratory&#xD;
             tests, study restrictions, and all study procedures LP.&#xD;
&#xD;
          -  Able to tolerate the anesthetic regimen required for LP procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any change in medications (excluding antiepileptic drugs) or diet intended to treat&#xD;
             symptoms of AS (e.g. sleeping aids, supplements, ketogenic or low-glycemic index diet,&#xD;
             other) over the prior 3 months before screening.&#xD;
&#xD;
          -  Inability to ambulate independently or with an assistive device or caregiver hand-hold&#xD;
&#xD;
          -  Any bleeding or platelet disorder&#xD;
&#xD;
          -  Any clinically significant (CS) cardiovascular, endocrine, hepatic, renal, pulmonary,&#xD;
             gastrointestinal, neurologic, malignant, metabolic, psychiatric, or other condition&#xD;
             that, in the judgment of the Investigator, will pose a safety risk, will make the&#xD;
             patient unsuitable for participation in, and/or unable to complete the study&#xD;
             procedures.&#xD;
&#xD;
          -  Any laboratory abnormality, that, in the Investigator's opinion, could adversely&#xD;
             affect the safety of the patient, make it unlikely that the course of treatment or&#xD;
             follow up would be completed, or impair the assessment of study result&#xD;
&#xD;
          -  Any active infection&#xD;
&#xD;
          -  Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or&#xD;
             unsuccessful lumbar puncture&#xD;
&#xD;
          -  Drugs that increase the risk of bleeding (e.g. heparin, low molecular weight heparin,&#xD;
             platelet inhibitors).&#xD;
&#xD;
          -  Use of any investigational oligonucleotide in the past 6 months&#xD;
&#xD;
          -  Any prior use of gene therapy&#xD;
&#xD;
          -  Use of any investigational drugs in the past 6 months&#xD;
&#xD;
          -  Any medical condition that would require intubation for the anesthesia procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Stromatt, MD</last_name>
    <role>Study Director</role>
    <affiliation>GeneTX Biotherapeutics, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Stromatt, MD</last_name>
    <phone>425-209-5817</phone>
    <email>info@genetxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erick Sell, MD</last_name>
      <email>esell@cheo.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Servais, MD PhD</last_name>
      <email>laurent.servais@paediatrics.ox.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

